Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Oscar B. Lahoud"'
Autor:
Bruno Almeida Costa, Jessica Flynn, Noriko Nishimura, Sean M. Devlin, Tasmin Farzana, Sridevi Rajeeve, David J. Chung, Heather J. Landau, Oscar B. Lahoud, Michael Scordo, Gunjan L. Shah, Hani Hassoun, Kylee Maclachlan, Malin Hultcrantz, Neha Korde, Alexander M. Lesokhin, Urvi A. Shah, Carlyn R. Tan, Sergio A. Giralt, Saad Z. Usmani, Karthik Nath, Sham Mailankody
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract Despite being the mainstay of management for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), there is limited data regarding the impact of tocilizumab (TCZ) and corticosteroids (CCS) on chi
Externí odkaz:
https://doaj.org/article/b0599253316a411c8f7c1eb08d801e0c
Autor:
Karthik Nath, Tala Shekarkhand, David Nemirovsky, Andriy Derkach, Bruno Almeida Costa, Noriko Nishimura, Tasmin Farzana, Colin Rueda, David J. Chung, Heather J. Landau, Oscar B. Lahoud, Michael Scordo, Gunjan L. Shah, Hani Hassoun, Kylee Maclachlan, Neha Korde, Urvi A. Shah, Carlyn Rose Tan, Malin Hultcrantz, Sergio A. Giralt, Saad Z. Usmani, Zainab Shahid, Sham Mailankody, Alexander M. Lesokhin
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract B-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple myeloma, but infections are emerging as a major challenge. In this retrospective, single-center analysis we evaluated infectious complications after BCMA-targ
Externí odkaz:
https://doaj.org/article/6b93aedeb2774601928a329b4bbfda19
Autor:
Carlyn Rose Tan, Andriy Derkach, David Nemirovsky, Amanda Ciardiello, Benjamin Diamond, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Urvi Shah, Kylee Maclachlan, Dhwani Patel, Oscar B. Lahoud, Heather J. Landau, David J. Chung, Gunjan L. Shah, Michael Scordo, Sergio A. Giralt, Alexander Lesokhin, Saad Z. Usmani, Ola Landgren, Neha Korde
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-8 (2023)
Abstract Lenalidomide and dexamethasone with bortezomib (VRd) or carfilzomib (KRd) are commonly used induction regimens in the U.S. This single-center, retrospective study evaluated outcomes and safety of VRd and KRd. Primary endpoint was progression
Externí odkaz:
https://doaj.org/article/cffbd554fa414cab9e44d309fb48abab